Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

NCT ID: NCT01730469

Last Updated: 2017-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-08-31
• Study Completion Date: 2012-04-30

Brief Summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects with mild, moderate, and severe renal impairment.

Detailed Description

This will be an open-label, non-randomized, multiple-center, sequential group, safety, tolerability, and PK study of a single dose of AT1001 (migalastat HCl, GR181413A) administered orally as a 150 mg dose in fasted healthy control male and female subjects with normal renal function compared to mild, moderate, and severe renally-impaired subjects (classified by level of creatinine clearance [CLcr] as determined by the Cockcroft-Gault formula).

Screening will occur from Day -28 to Day -2. Subjects will check-in to the clinic on Day -1 and receive a single oral dose of 150 mg AT1001 on Day 1. Subjects will be discharged from the clinic on Day 2 (if stable as determined by the Investigator) and return for daily visits on Day 3 through Day 6 for a safety assessment and PK sampling. Subjects will undergo a follow-up visit on Day 7 (+1) and an end of study visit on Day 10 (+1).

Conditions

Fabry Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AT1001 150 mg

Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast

Group Type: EXPERIMENTAL

AT1001 150 mg

Intervention Type: DRUG

AT1001 150mg is available as a capsule

Interventions

AT1001 150 mg

AT1001 150mg is available as a capsule

Intervention Type: DRUG

Other Intervention Names

migalastat HCl; GR181413A

Eligibility Criteria

Inclusion Criteria

• males or females aged 18 to 70 years inclusive (subjects with normal renal function, mild or moderate renal impairment), and 18 to 75 years inclusive (subjects with severe renal impairment)
• body mass index 18.0 to 40.0 kilogram (kg)/square meter (m^2) inclusive
• females who are non-pregnant, non-lactating, or postmenopausal for >=1 year, surgically sterile for >= 90 days, or agree to use approved methods of contraception
• males will be sterile or use approved methods of contraception
• understands and signs informed consent form Healthy subjects with normal renal function
• negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in
• good health with no clinically significant medical history, physical examination, vital signs, or 12-lead ECG
• clinical laboratory tests within the reference range or not clinically significant
• normal renal function (estimated CLcr >90 mL/min) at Screening Subjects with mild, moderate or severe renal impairment
• negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in or verification of a prescription for a positive test
• renal impairment (estimated CLcr <90 mL/min)
• evidence of stable renal impairment defined as two separate estimated CLcr values within 25%
• clinical laboratory results consistent with their renal condition or of no clinical significance for the study
• abnormal laboratory values must not be clinically significant. Anemia secondary to renal disease is acceptable if hemoglobin is ≥9 g/dL and no clinically significant symptoms. Liver enzymes and bilirubin must be below twice the upper normal level
• subjects with renal impairment must have stable underlying medical conditions < 90 days before study start
• stable medication regimen(s) (no new drug(s) or changed dosage(s) <30 days before study drug)
• in good general health, allowing for concurrent illnesses associated with chronic kidney disease

Exclusion Criteria

All subjects:

• history of hypersensitivity or allergies to any drug, unless approved by the Investigator and reviewed by Sponsor/Medical Monitor
• participation in a study with receipt of an investigational drug < 5 half-lives or 30 days (whichever is longer) before Check-in
• use of alcohol, grapefruit, or caffeine-containing foods or beverages < 72 hours before Check-in, unless approved by the Investigator and reviewed by the Sponsor/Medical Monitor
• poor peripheral venous access
• whole blood donation < 56 days before dosing or plasma donation < 14 days before dosing
• receipt of blood products < 2 months before Check-in
• history or presence of any clinically significant abnormal ECG
• history of alcoholism or drug addiction < 1 year before Check-in
• positive test for HIV antibody, HBsAg or anti-HCV
• pregnant or breastfeeding

Healthy subjects with normal renal function:

• use of any tobacco- or nicotine-containing products < 6 months before Check-in
• clinically significant (history of or active) cardiac, hepatic, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease putting the subject at increased risk or could interfere with study objectives
• screening laboratory values outside normal range and deemed clinically significant by the Investigator
• use of a prescription drug < 14 days of dosing or a non-prescription drug < 7 days before dosing or need of concomitant medication during the study

Subjects with mild, moderate, or severe renal impairment:

• unstable disease (concurrent medical conditions that have changed significantly < 90 days)
• changes in concomitant prescription medications < 30 days before dosing or expected changes during study
• use of new non-prescription medication < 30 days before dosing
• renal transplant
• acute or chronic non-renal condition limiting the subject's ability to complete and/or participate in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Amicus Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor, Clinical Research

Role: STUDY_DIRECTOR

Amicus Therapeutics

Locations

GSK Investigational Site

Costa Mesa, California, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Orlando, Florida, United States

Countries

United States

References

Johnson FK, Mudd PN Jr, DiMino T, Vosk J, Sitaraman S, Boudes P, France N, Barlow C. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function. Clin Pharmacol Drug Dev. 2015 Jul;4(4):256-61. doi: 10.1002/cpdd.149. Epub 2014 Dec 22.

Reference Type: DERIVED

PMID: 27136905 (View on PubMed)

Other Identifiers

116431

Identifier Type: -

Identifier Source: org_study_id